je.st
news
Tag: survival
Feed Mill VFD Survival Strategy Webinar
2016-07-15 16:15:00| National Hog Farmer
An upcoming VFD Survival Strategy webinar series, hosted by GlobalVetLINK, will provide information and resources from leading veterinarians and industry experts to help with preparation for compliance with Veterinary Feed Directives. Location GlobalVetLINK VFD Survival Strategy webinar United States See map: Google Maps A “VFD Survival Strategy” webinar series, hosted by GlobalVetLINK, will provide information and resources from leading veterinarians and industry experts to help with preparation for compliance with Veterinary Feed Directives. With the new VFD regulations changes coming in January, many in the industry still have questions about how the changes will affect their business. The VFD Survival Strategy webinars are offered for individual stakeholder groups — including feed distributors, veterinarians and producers of swine, beef, dairy and poultry. Topics covered during the webinars include education about VFDs and the coming changes, clarification about interpretation of the rule, actions to take now to prepare and resources available to help with compliance. Each webinar will also provide an opportunity for webinar attendees to ask presenters questions about the 2017 VFD transition. This webinar is presented by Phil Lawler, Principal at PDT Consultants LCC. For additional details and to register for this webinar, as well as information on a veterinarian and species-specific webinars, visit www.globalvetlink.com/vfdsurvivalwebinars. read more
Tags: feed
strategy
survival
mill
Chasing Survival: Many Species Face Climate Change's Ultimate Test
2016-06-27 10:59:00| Climate Ark Climate Change & Global Warming Newsfeed
InsideClimate: Roughly half of the world's species are currently on the move. As global warming drives ocean and air temperatures higher, they are chasing the habitats they are accustomed toheading further north or to higher elevations or following the trail of their food sources. Those that can't keep up with the pace of change face extinction, and if warming continues at its current pace, one in six species is projected to go extinct. That number falls to one in 20 if the rise is constrained to 2 degrees Celsius,...
Tags: test
face
ultimate
species
Survival of the Chicest
2016-06-21 15:56:00| Happi Breaking News
Nars will launch a Nordstrom exclusive.
Mercks KEYTRUDA (pembrolizumab) Demonstrates Superior Progression-Free and Overall Survival Compared to Chemotherapy as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer
2016-06-16 12:45:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KEYNOTE-024 Studied Patients Whose Tumors Expressed High Levels of PD-L1 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the KEYNOTE-024 trial investigating the use of KEYTRUDA (pembrolizumab), in patients with previously untreated advanced non-small cell lung cancer (NSCLC) whose tumors expressed high levels of PD-L1 (tumor proportion score of 50 percent or more), met its primary endpoint. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Courtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: advanced
cell
treatment
compared
New KEYTRUDA (pembrolizumab) Data from KEYNOTE-010 and KEYNOTE-001 in Advanced Non-Small Cell Lung Cancer, Including Survival Data, To Be Presented at 2016 ASCO Annual Meeting
2016-06-04 14:00:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. New Analysis from KEYNOTE-010, Comparing KEYTRUDA to Chemotherapy, Shows Improved Survival Benefit in Patients with Increased Levels of PD-L1 Expression KEYNOTE-001 Findings Show Responses Are Durable and Include Two Year Overall Survival Data for KEYTRUDA KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data, including updated response rates, progression-free survival (PFS) and overall survival (OS) with KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, as a monotherapy in patients with advanced non-small cell lung cancer (NSCLC) whose tumors express PD-L1 from two studies: KEYNOTE-010 and KEYNOTE-001. Language: English Contact: MerckMedia Contacts:Pamela Eisele, (267) 305-3558orCourtney Ronaldo, (908) 236-1108orInvestor Contacts:Teri Loxam, (908) 740-1986orJustin Holko, (908) 740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: including
data
advanced
presented
Sites : [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] next »